唑来膦酸治疗老年男性原发性骨质疏松的临床效果评估

【目的】评估唑来膦酸治疗老年男性原发性骨质疏松患者的临床效果。【方法】将76名年龄≥70岁的男性原发性骨质疏松患者随机分为两组。对照组（n＝39）每日补充钙剂和维生素D，治疗组（n＝37）在对照组的基础上给予一次静脉滴注唑来膦酸5 mg。随访12个月后观察所有研究对象骨密度和骨代谢标记物水平变化。【结果】治疗组的椎骨、全髋骨和股骨颈骨密度均显著高于对照组（P＜0．05）；血液骨代谢标记物β-CTx、PINP和BSAP水平则显著低于对照组（P ＜0．05），两组严重不良反应发生率分别为24．32％和23．08％，差异无统计学意义（P＞0．05）。【结论】唑来膦酸治疗一年后可以显著提高患者骨密度和降低骨代谢标记物水平，降低老年男性原发性骨质疏松患者的骨折危险。

Assessment of Clinical Efficacy of Zoledronic Acid for the Treatment of Elderly Male Patients with Primary Osteoporosis

Objective]To evaluate clinical efficacy of zoledronic acid for the treatment of elderly male pa-tients with primary osteoporosis.Methods]A total of 76 male patients with primary osteoporosis were ran-domly divided into 2 groups.The control group（n=39）was supplemented with calcium and vitamin D daily, while the treatment group（n=37）was given an intravenous drip infusion of zoledronic acid 5mg once based on the treatment of control group.The changes of bone mineral density and bone metabolism markers of all pa-tients were observed after 1 2 months of follow up.Results]Bone mineral density of lumbar spine,total hip and femoral neck in treatment group was significantly higher than that in control group.Serum levels of bone metabolism markers such asβ-C-terminal telopeptide of type I collagen（β-CTx）,procollagen type I N-terminal propeptide（PINP）and bone-specific alkaline phosphatase（BSAP）in treatment group were significantly lower than those in control group（P0.05）.Conclusion]Zoledronic acid treatment for 1 year can markedly increase bone mineral density,decrease serum levels of bone metabolism markers and reduce the risk of fracture in elderly male patients with primary osteoporosis.